Department of Orthopaedic Surgery, Meir Medical Center, Kfar Saba, Israel.
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Am J Sports Med. 2022 Apr;50(5):1442-1450. doi: 10.1177/03635465211003613. Epub 2021 Apr 15.
Tissue adhesives (TAs) represent a promising alternative or augmentation method to conventional tissue repair techniques. In sports medicine, TA use has been suggested and implemented in the treatment of meniscal tears. The aim of this review was to present and discuss the current evidence and base of knowledge regarding the clinical usage of TAs for meniscal repair.
Systematic review; Level of evidence, 4.
A systematic literature search was performed using the PubMed, Embase, and Cochrane Library databases for studies reporting on clinical outcomes of TA usage for meniscal repair in humans in the English language published before January 2020.
Ten studies were eligible for review and included 352 meniscal repairs: 94 (27%) were TA-based repairs and 258 (73%) were combined suture and TA repairs. Concomitant anterior cruciate ligament reconstruction was performed in 224 repairs (64%). All included studies utilized fibrin-based TA. Of the 10 studies, 9 were evidence level 4 (case series), and 8 reported on a cohort of ≤40 meniscal repairs. Rates of meniscal healing were evaluated in 9 of 10 studies, with repair failure seen in 39 repairs (11%).
The use of TAs, specifically fibrin-based TAs, for meniscal repair shows good results as either an augmentation or primary repair of various configurations of meniscal tears. However, this review reveals an absence of comparative high-quality evidence supporting the routine use of TAs for meniscal repair and emphasizes the lack of an ideal TA designed for that purpose. Further high-quality research, basic science and clinical, will facilitate the development of new materials and enable testing their suitability for use in meniscal repair.
组织粘合剂(TAs)代表了一种有前途的替代或增强传统组织修复技术的方法。在运动医学中,TA 的使用已被建议并应用于治疗半月板撕裂。本综述的目的是介绍和讨论 TA 用于半月板修复的临床应用的当前证据和知识基础。
系统评价;证据水平,4 级。
使用 PubMed、Embase 和 Cochrane 图书馆数据库进行系统文献检索,检索在 2020 年 1 月之前以英文发表的关于 TA 用于人类半月板修复的临床结果的研究。
有 10 项研究符合纳入标准,共纳入 352 例半月板修复:94 例(27%)为 TA 修复,258 例(73%)为缝线和 TA 联合修复。224 例(64%)同时进行前交叉韧带重建。所有纳入的研究均使用纤维蛋白 TA。在这 10 项研究中,有 9 项为 4 级证据(病例系列),8 项报告了≤40 例半月板修复的队列研究。9 项研究中有 8 项评估了半月板愈合率,39 例(11%)修复失败。
TAs,特别是纤维蛋白 TA,用于半月板修复显示出良好的结果,无论是各种类型的半月板撕裂的增强或主要修复。然而,本综述揭示了缺乏支持 TA 常规用于半月板修复的高质量证据,并强调缺乏为此目的设计的理想 TA。进一步的高质量研究、基础科学和临床研究将促进新材料的发展,并能够测试其在半月板修复中的适用性。